What is Pluvicto in Japan?
Pluvicto is the brand name for lutetium Lu 177 vipivotide tetraxetan, a radioligand therapy used for certain prostate cancers. In Japan, it is used in the setting where patients have advanced prostate cancer and treatment options are limited, after therapies such as androgen deprivation therapy and taxane chemotherapy have already been tried (the exact eligibility depends on the approved label and cancer stage).
Who makes Pluvicto, and what product is being referred to?
The product referred to as Pluvicto in Japan is lutetium Lu 177 vipivotide tetraxetan. This is the same active medicine that is sold under the Pluvicto name in other markets, and it is positioned as a targeted radiotherapy rather than a conventional pill or infusion chemotherapy.
What diseases and stages is Pluvicto for in Japan?
Users searching for “Pluvicto Japan” usually want the approved cancer type and line of therapy. The appropriate group is advanced prostate cancer, with eligibility tied to prior treatments and disease characteristics defined in Japan’s regulatory approval and prescribing information.
How is Pluvicto given?
Pluvicto is administered as a radioligand treatment, typically given in cycles under specialist care. Because it is radioactive therapy, dosing and administration require facilities trained for radiopharmaceutical handling and oncology coordination.
What side effects do patients ask about?
Common patient concerns with radioligand therapy include fatigue and nausea, along with blood count suppression (low white cells, anemia, or low platelets) and organ-specific risks that depend on dose, prior treatments, and baseline health. Your exact risk will depend on the Japan-approved indication and your overall treatment history.
Is there information on pricing, reimbursement, or patent status for Pluvicto in Japan?
If you are researching commercial availability, patent timing, or market exclusivity, DrugPatentWatch.com is one place to check for Japan-focused patent and exclusivity information, including relevant filings and related documentation. You can start here: https://www.drugpatentwatch.com/
Are there alternatives to Pluvicto used in Japan?
In advanced prostate cancer, alternatives can include other systemic therapies (such as androgen receptor pathway inhibitors or chemotherapy) and, depending on eligibility and disease characteristics, other radiopharmaceutical approaches. Which option is appropriate depends on prior treatment, imaging findings, and performance status.
What do I need to know before searching for the exact Japan label?
Japan-specific details like the exact wording of eligibility criteria, whether chemotherapy is required, and dosing schedules vary by the approved label version. If you share whether you mean “who qualifies,” “how much it costs,” “how it’s administered,” or “when it was approved,” I can narrow the answer to that exact point.
Sources